Koch Armin
Bundesinstitut für Arzneimittel und Medizinprodukte, Kurt-Georg-Kiesinger Allee 3, 53175 Bonn, Germany.
Biom J. 2006 Aug;48(4):574-85. doi: 10.1002/bimj.200510239.
Adaptive designs are one of the most promising developments in statistics with applications to clinical trials. Obviously, knowledge at the beginning of a clinical trial will always be limited. Thus it may seem logical that the knowledge from accumulating information should be used to optimize the design of the trial. This paper discusses conditions under which this may be possible in phase III clinical trials where the principal aim is confirmation of hypotheses that have been developed in earlier stages of drug development.
适应性设计是统计学领域最具前景的发展之一,应用于临床试验。显然,在临床试验开始时所掌握的知识总是有限的。因此,利用积累信息所获得的知识来优化试验设计似乎是合乎逻辑的。本文讨论了在III期临床试验中实现这一点的条件,III期临床试验的主要目的是证实药物研发早期阶段所提出的假设。